PCSK9 Pick-Me-Up: New Cholesterol Guidelines May Mean Lower LDL Targets
Executive Summary
Sales of PCSK9 inhibitors have been improving, though are still low, and inclusion of lower LDL-C targets in practice guidelines coming this November would be a boost.
You may also be interested in...
PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Sanofi and Regeneron’s Praluent could draw even with Amgen’s US Repatha in approved FDA indications in 2019. While the injectable PCSK9 inhibitors battle for payers and prescribers, Esperion is readying its oral bempedoic acid to join the lipid-lowering fray – and strategizing towards what could be the first statin intolerance indication.
Harper, Hooper Exit As Amgen Revenues Rise
Amgen revealed better-than-expected second quarter earnings July 26 and said its R&D and commercial heads Sean Harper and Anthony Hooper are retiring. Harper, who's getting involved with start-ups, is being replaced from within by David Reese; Bristol's Murdo Gordon will take over for Hooper.
Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It
Express Scripts has agreed to give Praluent preferred access over Amgen's Repatha on its national formulary and is removing restrictions that have been a significant barrier to market access for the PCSK9 inhibitors.